GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMF) » Definitions » Cyclically Adjusted Price-to-FCF

Astellas Pharma (Astellas Pharma) Cyclically Adjusted Price-to-FCF : 13.41 (As of Apr. 29, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Astellas Pharma Cyclically Adjusted Price-to-FCF?

As of today (2024-04-29), Astellas Pharma's current share price is $9.521. Astellas Pharma's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $0.71. Astellas Pharma's Cyclically Adjusted Price-to-FCF for today is 13.41.

The historical rank and industry rank for Astellas Pharma's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

ALPMF' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 14.83   Med: 20.99   Max: 28.14
Current: 15.09

During the past years, Astellas Pharma's highest Cyclically Adjusted Price-to-FCF was 28.14. The lowest was 14.83. And the median was 20.99.

ALPMF's Cyclically Adjusted Price-to-FCF is ranked better than
79.2% of 327 companies
in the Drug Manufacturers industry
Industry Median: 32.38 vs ALPMF: 15.09

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Astellas Pharma's adjusted free cash flow per share data for the three months ended in Dec. 2023 was $0.139. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $0.71 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Astellas Pharma Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Astellas Pharma's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Cyclically Adjusted Price-to-FCF Chart

Astellas Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.88 20.57 18.20 20.09 18.53

Astellas Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.27 18.53 21.37 20.68 16.89

Competitive Comparison of Astellas Pharma's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, Astellas Pharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Cyclically Adjusted Price-to-FCF falls into.



Astellas Pharma Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Astellas Pharma's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=9.521/0.71
=13.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astellas Pharma's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Astellas Pharma's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.139/106.8000*106.8000
=0.139

Current CPI (Dec. 2023) = 106.8000.

Astellas Pharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 0.146 95.700 0.163
201406 0.193 98.000 0.210
201409 0.129 98.500 0.140
201412 0.101 97.900 0.110
201503 0.021 97.900 0.023
201506 0.053 98.400 0.058
201509 0.224 98.500 0.243
201512 0.067 98.100 0.073
201603 0.437 97.900 0.477
201606 0.043 98.100 0.047
201609 0.273 98.000 0.298
201612 0.331 98.400 0.359
201703 0.157 98.100 0.171
201706 0.233 98.500 0.253
201709 0.203 98.800 0.219
201712 0.383 99.400 0.412
201803 0.404 99.200 0.435
201806 0.125 99.200 0.135
201809 0.304 99.900 0.325
201812 0.353 99.700 0.378
201903 0.176 99.700 0.189
201906 -0.015 99.800 -0.016
201909 0.357 100.100 0.381
201912 0.217 100.500 0.231
202003 0.152 100.300 0.162
202006 -0.058 99.900 -0.062
202009 0.426 99.900 0.455
202012 0.489 99.300 0.526
202103 0.313 99.900 0.335
202106 0.099 99.500 0.106
202109 0.349 100.100 0.372
202112 0.276 100.100 0.294
202203 0.143 101.100 0.151
202206 0.125 101.800 0.131
202209 0.266 103.100 0.276
202212 0.210 104.100 0.215
202303 0.358 104.400 0.366
202306 -0.016 105.200 -0.016
202309 0.022 106.200 0.022
202312 0.139 106.800 0.139

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Astellas Pharma  (OTCPK:ALPMF) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Astellas Pharma Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Astellas Pharma (Astellas Pharma) Business Description

Traded in Other Exchanges
Address
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.

Astellas Pharma (Astellas Pharma) Headlines

From GuruFocus